ANI Pharmaceuticals, Inc.
ANIP
$82.72
-$0.05-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 88.07% | 367.52% | 210.14% | 473.81% | -13.87% |
| Total Depreciation and Amortization | -8.61% | 0.06% | 43.71% | 58.41% | 55.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 254.42% | -14.45% | 0.61% | -18.54% | -11.62% |
| Change in Net Operating Assets | -71.26% | -461.43% | -314.16% | 904.35% | 113.00% |
| Cash from Operations | 66.83% | 91.47% | 253.17% | 335.35% | 91.53% |
| Capital Expenditure | -145.51% | 48.04% | -26.83% | 9.78% | 45.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.78% | -84.88% | 90.49% | -- | -- |
| Cash from Investing | 42.94% | 86.86% | 98.45% | -55.29% | -322.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.05% | -100.05% | 99.31% | -170.80% | -170.80% |
| Issuance of Common Stock | -13.10% | -97.76% | 721.31% | 23.58% | -2.20% |
| Repurchase of Common Stock | -97.49% | -92.14% | -53.53% | 57.62% | -15.49% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 100.00% | 15.27% | 0.00% | 0.00% |
| Other Financing Activities | -- | 100.00% | 99.96% | -- | -- |
| Cash from Financing | -118.21% | 5.52% | -97.82% | -20.32% | 49.78% |
| Foreign Exchange rate Adjustments | 152.53% | -242.53% | 868.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 417.83% | 18,778.86% | 147.13% | 490.61% | -33.90% |